Skip to main content
    M

    Moderna Inc (MRNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $215.27
    -8.10 (-3.63%)

    Market Cap: $90.38B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Moderna Inc (MRNA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 6, 2026. Financial statements from company filings, amounts in US dollars.

    Moderna reported revenue of $1.94B for the fiscal year ended Dec 31, 2025, down 39.9% from the year before. That year, net income was -$2.82B with a net margin of -145.2%, operating cash flow was -$1.87B and free cash flow was -$2.06B. The quarter ended Sep 30, 2026 had revenue of $1.31B and net income of $162.00M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $108.40M, a compound annual rate of 37.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$1.94B-39.9%55.3%-158.1%-145.2%
    Dec 2024$3.24B-52.7%54.8%-121.9%-110.0%
    Dec 2023$6.85B-64.4%31.5%-61.9%-68.8%
    Dec 2022$19.26B+4.3%71.9%48.9%43.4%
    Dec 2021$18.47B+2200.2%85.8%72.0%66.1%
    Dec 2020$803.00M+1238.3%99.0%-95.0%-93.0%
    Dec 2019$60.00M-55.6%100.0%-910.0%-856.7%
    Dec 2018$135.07M-34.4%100.0%-306.0%-284.8%
    Dec 2017$205.82M+89.9%100.0%-130.9%-124.3%
    Dec 2016$108.40MN/A100.0%-206.4%-199.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$1.94B$3.24B$6.85B$19.26B$18.47B$803.00M$60.00M$135.07M$205.82M$108.40M
    Cost of revenue$868.00M$1.46B$4.69B$5.42B$2.62B$8.00M$0$0$0$0
    Gross profit$1.08B$1.77B$2.15B$13.85B$15.85B$795.00M$60.00M$135.07M$205.82M$108.40M
    Research and development$3.13B$4.54B$4.84B$3.29B$1.99B$1.37B$496.00M$454.08M$410.46M$274.72M
    Operating income-$3.07B-$3.94B-$4.24B$9.42B$13.30B-$763.00M-$546.00M-$413.27M-$269.36M-$223.77M
    Net income-$2.82B-$3.56B-$4.71B$8.36B$12.20B-$747.00M-$514.00M-$384.73M-$255.92M-$216.21M
    EBITDA-$2.93B-$3.94B-$3.80B$9.75B$13.55B-$728.00M-$527.00M-$388.44M-$249.61M-$208.89M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.31B$145.00M$389.00M$678.00M$1.02B$142.00M$108.00M$966.00M$1.86B$241.00M$167.00M$2.81B
    Gross profit$995.00M$52.00M-$566.00M$226.00M$809.00M$23.00M$18.00M$227.00M$1.35B$126.00M$71.00M$1.88B
    Operating income$130.00M-$815.00M-$1.39B-$857.00M-$260.00M-$907.00M-$1.05B-$1.25B-$70.00M-$1.36B-$1.27B$6.00M
    Net income$162.00M-$782.00M-$1.34B-$826.00M-$200.00M-$825.00M-$971.00M-$1.12B$13.00M-$1.28B-$1.18B$217.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded long-term debt of $590.00M by $2.00B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$12.34B$14.14B$18.43B$25.86B$24.67B$7.34B$1.59B$2.02B$1.08B$1.42B
    Current assets$6.54B$8.10B$10.32B$13.43B$16.07B$6.30B$1.13B$37.05M$783.22M$1.09B
    Cash and equivalents$2.60B$1.93B$2.91B$3.21B$6.85B$2.62B$235.88M$658.36M$134.86M$50.08M
    Total liabilities$3.69B$3.24B$4.57B$6.74B$10.52B$4.78B$414.61M$354.99M$459.19M$575.31M
    Short-term debtN/A$37.00M$25.00M$196.00M$211.00M$30.00M$67.65M$79.07M$72.72M$25.05M
    Long-term debt$590.00M$0N/AN/AN/AN/AN/AN/A$15.69M$12.50M
    Shareholder equity$8.65B$10.90B$13.85B$19.12B$14.14B$2.56B$1.17B-$982.43M-$551.37M$841.85M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$13.47B$10.96B$11.49B$12.34B$12.13B$12.01B$12.70B$14.14B$15.80B$15.68B$16.73B$18.43B
    Total liabilities$6.63B$4.20B$4.08B$3.69B$2.81B$2.61B$2.64B$3.24B$3.88B$3.97B$3.91B$4.57B
    Cash and equivalents$1.20B$1.72B$1.91B$2.60B$1.13B$1.28B$1.62B$1.93B$1.64B$2.48B$2.05B$2.91B
    Shareholder equity$6.84B$6.76B$7.41B$8.65B$9.33B$9.40B$10.07B$10.90B$11.93B$11.71B$12.82B$13.85B
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$1.87B-$3.00B-$3.12B$4.98B$13.62B$2.03B-$459.00M-$330.87M-$331.48M$66.73M
    Capital expenditures$192.00M$1.05B$707.00M$400.00M$284.00M$68.00M$32.00M$105.77M$58.40M$33.14M
    Free cash flow-$2.06B-$4.05B-$3.83B$4.58B$13.34B$1.96B-$491.00M-$436.63M-$389.88M$33.59M
    Dividends paidN/AN/A$270.00M$184.00M$124.00M$7.04MN/AN/A$1.48M$633.00K
    Share repurchases$2.00M$0$1.15B$3.33B$857.00M$0$0N/AN/AN/A
    Investing cash flow$1.95B$1.95B$4.21B-$5.18B-$8.52B-$1.67B-$15.00M-$373.09M$417.36M-$648.61M
    Financing cash flow$593.00M$56.00M-$1.38B-$3.45B-$873.00M$2.03B$52.00M$1.23B$168.00K$472.91M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$1.56B-$526.00M-$630.00M$930.00M-$847.00M-$919.00M-$1.04B$825.00M-$1.57B-$1.27B-$989.00M$622.00M
    Capital expenditures$47.00M$37.00M$62.00M$39.00M$33.00M$3.00M$117.00M$522.00M$151.00M$182.00M$196.00M$220.00M
    Free cash flow-$1.61B-$563.00M-$692.00M$891.00M-$880.00M-$922.00M-$1.15B$303.00M-$1.72B-$1.46B-$1.19B$402.00M
    Last 12 quarters

    Frequently Asked Questions About MRNA

    What is Moderna's annual revenue?

    Moderna reported revenue of $1.94B for the fiscal year ended Dec 31, 2025.

    How fast is Moderna's revenue growing?

    Revenue was down 39.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -53.4%.

    Is Moderna profitable?

    No. Moderna reported net income of -$2.82B for the fiscal year ended Dec 31, 2025, with a net margin of -145.2%.

    How much free cash flow does MRNA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$1.87B minus capital expenditures of $192.00M produced free cash flow of -$2.06B.

    How much debt does Moderna have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $590.00M and cash and equivalents of $2.60B.